Design of Phase II Cancer Trials for Evaluation of Cytostatic/Cytotoxic Agents

REFERENCES

• Dent , S. , Zee , B. , Dancey , J. , Hanauske , A. , Wanders , J. , Eisenhauer , E. ( 2001 ). Application of a new multinomial Phase II stopping rule using response and early progression . J. Clin. Oncol. 19 : 785 – 791 .
   PubMed Web of Science ®Google Scholar
• Fleming , T. R. ( 1982 ). One sample multiple testing procedure for Phase II clinical trials . Biometrics 38 : 143 – 151 .
   PubMed Web of Science ®Google Scholar
• Freidlin , B. , Dancey , J. , Korn , E. L. , Zee , B. , Eisenhauer , E. ( 2002 ). Multinomial Phase II trial designs (correspondence) . J. Clin. Oncol. 20 : 599 .
   PubMed Web of Science ®Google Scholar
• Karrison , T. G. , Maitland , M. L. , Stadler , W. M. , Ratain , M. J. ( 2007 ). Design of Phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non–small-cell lung cancer . J. Natl. Cancer Inst. 99 : 1455 – 1461 .
   PubMed Web of Science ®Google Scholar
• Lin , S. P. , Chen , T. T. ( 2003 ). Multiple-stage designs for phase II cancer trials . In: Encyclopedia of Biopharmaceutical Statistics . New York : Marcel Dekker, Inc .
   Google Scholar
• Simon , R. ( 1989 ). Optimal two-stage designs for phase II clinical trials . Control Clin. Trials 10 : 1 – 10 .
   PubMedGoogle Scholar
• Therasse , P. , Arbuck , S. G. , Eisenhauer , E. A. , Wanders , J. , Kaplan , R. S. , Rubinstein , L. , Verweij , J. , Van Glabbeke , M. , Van Oosterom , A. T. , Christian , M. C. , Gwyther , S. G. ( 2000 ). New guidelines to evaluate the response to treatment in solid tumors . J. Natl. Cancer Inst. 92 : 205 – 216 .
   PubMed Web of Science ®Google Scholar
• Zee , B. , Melnychuk , D. , Dancey , J. , Eisenhauer , E. ( 1999 ). Multinomial phase II cancer trials incorporating response and early progression . J. Biopharmaceutical Statistics 9 : 351 – 363 .
   PubMedGoogle Scholar